Project Grant R01AI186249
Award Date
6/6/25
Completion Date
5/31/30
Dollars Obligated
$530K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $218,900.00 to the University of Alabama at Birmingham to conduct research on elucidating the proteolytic determinants of flavivirus infection. The research aims to advance understanding of the molecular factors influencing flavivirus protease cleavage of intracellular substrates and the impact on viral fitness....
The Project Grant award of $515,282.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to provide a detailed understanding of the molecular mechanisms underlying HIV spread through cell-to-cell contact. The research will leverage a novel flow cytometry assay and APEX proximity labeling technology to identify determinants and composition of the virological synapse, analyze how synapse formation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $760,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The grant funding supports research to develop recombinant enhanced antiviral sensors (REAVRs) that can broadly inhibit known and emerging viruses to control or prevent vector-borne and zoonotic viral diseases. Specifically, the project aims to: 1) generate and optimize REAVRs and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The project aims to elucidate the mechanisms driving the development of chronic Chikungunya virus (CHIKV) arthritis, a debilitating condition affecting up to 50% of CHIKV patients. The research will define the viral reservoir in macrophages, assess mechanisms driving pro-inflammatory...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $184,109 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, with a project period from December 2024 to November 2026. The grant supports research to investigate the role of immune inhibitory receptors in modulating monocyte and T cell functions during subclinical Plasmodium falciparum malaria...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $932,750.00 to Emory University to develop and utilize single cell techniques to gain unprecedented insight into West Nile Virus (WNV) infection of the lymphatics and spleen. The goal is to better define the cellular targets of WNV infection and understand how the antiviral immune response limits virus...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $805,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai. The grant, awarded on November 20, 2024, will fund a 5-year research project titled "Understanding the Tropism and Pathogenesis of Pararubulaviruses." The research aims to elucidate the cellular tropism, receptor usage, and pathogenesis mechanisms of Menangle and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $46,715,173 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Washington University in St. Louis to establish the Flavivirus and Alphavirus REVAMPP (FLARE) Center. The FLARE Center will develop and optimize protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody (mAb)-based treatments, to rapidly respond to emerging flaviviruses and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $245,895.00 to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on using CRISPR-Cas9 base editing approaches to systematically identify ubiquitination events that promote flavivirus infection. The research aims to discover novel pathways that facilitate flavivirus infection and provide...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $220,224 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Chicago. This grant supports computational investigations into the assembly, maturation, and uncoating processes of the HIV-1 virus. The research aims to enhance the mechanistic understanding of how viral RNA is packaged, which could aid in the design of future therapeutics targeting viral assembly and...